Citable filing context
BSX's research view summarizes recent SEC filing context, starting with earnings from Jul 29, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 29, 2026 | earnings | Boston Scientific reported Q2 2026 net sales of $5.442 billion, a 7.5% increase year-over-year. |
| Jul 27, 2026 | restructuring | Boston Scientific announced a 2026 restructuring plan with estimated pre-tax charges of $700 million to $800 million. |
| May 18, 2026 | share_repurchase | Boston Scientific entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank. |
| Jul 29, 2026 | Guidance: adjusted_eps | 3.28 to 3.32 |
| Jul 29, 2026 | Guidance: adjusted_eps | 0.80 to 0.82 |
| Jul 29, 2026 | Guidance: organic_net_sales_growth | 5.00 to 6.00 |
| Aug 3, 2026 | mda_quarterly | Boston Scientific reported strong financial performance for the first half of 2026, with net sales reaching $10.65 billion, a 9.5% increase over the prior year. Growth was primarily driven by the Cardiovascular segment, specifically the Farapulse Pulsed Field Ablation system and the AGENT drug-coated balloon, alongside the Endoscopy business. The company’s operating income rose to $2.28 billion, bolstered by higher sales volumes and improved gross margins, which reached 70.1% for the six-month period. Strategic expansion remains a priority, with the company currently awaiting regulatory clearance for the $14.5 billion acquisition of Penumbra, Inc., which will be integrated into the Cardiovascular division. Additionally, Boston Scientific invested $1.6 billion in MiRus LLC, securing an exclusive option to acquire its TAVR structural heart business. To support long-term efficiency, the company initiated a new global restructuring program in July 2026, expected to incur $700–$800 million in pre-tax charges through 2029. Key risks include ongoing litigation, such as the recently consolidated Multi-District Litigation regarding spinal cord stimulation products, and potential macroeconomic volatility, including trade policy shifts and tariff impacts. The company maintains a solid liquidity position, supported by new credit agreements and a $5 billion share repurchase authorization, of which $3 billion remains available. |
| May 1, 2026 | mda_quarterly | Boston Scientific reported first-quarter 2026 net sales of $5.2 billion, an 11.6% increase, with 9.4% organic growth. Reported net income rose to $1.34 billion, bolstered by higher sales and a $384 million discrete tax benefit. The Cardiovascular segment led performance with 13.5% growth, driven by the Farapulse Pulsed Field Ablation System, WATCHMAN Left Atrial Appendage Closure Devices, and AGENT Drug-Coated Balloons, despite increased competition and a deceleration in WATCHMAN procedures. Neuromodulation grew 17.4%, led by the Intracept Intraosseous Nerve Ablation and Nalu Peripheral Nerve Stimulation systems. In contrast, Urology growth was constrained to 2.1% by volume-based procurement in China and sacral neuromodulation commercial disruptions. Gross margin improved to 69.4% due to a higher-margin product mix. A significant strategic focus is the $14.5 billion acquisition of Penumbra, which is currently subject to an FTC Second Request. The company maintains a strong liquidity position with $1.45 billion in cash and a 1.87x leverage ratio, well within its 4.25x covenant. Management remains cautious regarding macroeconomic risks, specifically global trade policy uncertainty, tariff volatility, and potential supply chain disruptions. |
Source: SEC EDGAR filing text and events; period Jul 29, 2026; filed Jul 29, 2026.
BSX company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.